We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Read MoreHide Full Article
Key Takeaways
Tempus AI raised its 2025 sales forecast to $1.26B after 89.6% Q2 revenue growth.
TEM's gross profit surged 158.3% with margin gains, while adjusted EBITDA loss narrowed.
Acquisitions like Paige and Deep 6 AI expand TEM's datasets and healthcare reach.
Tempus AI (TEM - Free Report) posted robust second-quarter results and raised the sales guidance for 2025 for the second time within six months. Full-year revenues are now expected to be approximately $1.26 billion (earlier $1.25 billion), indicating nearly 82% annual growth. The company recorded second-quarter revenue growth of 89.6%. The quarterly gross profit soared 158.3% from the year-ago quarter’s level.
Additionally, adjusted gross margin expanded 1649 bps, despite a 32.2% rise in the cost of revenues. Meanwhile, Tempus AI experienced another quarter of sequential improvement in adjusted EBITDA, which went from a negative $16 million in the previous quarter to a negative $5.6 million in the second quarter. This improvement made the company expect a positive adjusted EBITDA of $5 million in 2025.
On the innovation side, Tempus AI continued to push boundaries. Recently, the company expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer to address critical care gaps in breast cancer care. It also introduced xM, a liquid biopsy assay, for treatment response monitoring (TRM), to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors.
Year to date, TEM stock has skyrocketed 137.6%, outperforming the Medical Info Systems industry and the S&P 500 benchmark, which have improved about 24.7% and 10.8%, respectively. The company has also outperformed other players in the health infotech field, such as Azenta, Inc. (AZTA - Free Report) and 10x Genomics, Inc. (TXG - Free Report) , which have lost 41% and 2.9%, respectively, during the said period.
YTD TEM’s Price Performance
Image Source: Zacks Investment Research
With strong financial growth and groundbreaking innovations, Tempus AI is rapidly positioning itself as a leader in precision medicine and AI-driven healthcare. For investors, now is the time to gauge just how big this runway could get.
Developments Propelling TEM’s Growth
Key Acquisitions Strengthening Its Leadership Position: Tempus announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition, valued at $81.25 million, is expected to enable Tempus to expand its dataset and strengthen its experienced technical team.
Additionally, in March, Tempus acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. The Deep 6 AI deal expanded Tempus' reach to 30M patient records across 750 healthcare providers.
Furthermore, earlier this year, Tempus completed the acquisition of Ambry Genetics, a genetic testing company that specializes in hereditary cancer screening and other genetic diseases. By combining Ambry’s genetic testing strengths with Tempus’ AI and data tools, the latter broadened its healthcare offerings into new areas, like pediatrics, women's health, rare disease, immunology and cardiology.
Robust Segmental Performance: In the second quarter, Tempus reported robust growth in its Genomics business with sales surging 115% year over year, driven by accelerating oncology testing volumes, which rose 26%. The hereditary testing segment also contributed significantly, with volumes up 32%, benefiting from both market share gains and overall industry tailwinds.
Meanwhile, Data and Services revenues grew 35.7%, led by a 41% rise in Insights, the company’s data licensing business. This growth was fueled by strong demand from large pharma partnerships, including the recently signed AstraZeneca Pathos deal, which contributed around $16 million in revenues for the quarter.
Strong Balance Sheet: Tempus exited the second quarter of 2025 with $293.0 million in cash and marketable securities, reflecting an improvement of approximately $70 million over the previous quarter. The company reported no current debt during the quarter, indicating strong solvency. Just after quarter end, Tempus AI completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing its balance sheet and allowing it to replace a portion of the existing term loan with a significantly lower interest debt instrument.
Estimates for TEM Heading South
The Zacks Consensus Estimate for Tempus’ 2025 sales and EPS implies a year-over-year improvement of 81.2% and 56.3%, respectively. However, in the past 30 days, Tempus’ loss per share estimate for 2025 has moved south 3%.
Image Source: Zacks Investment Research
Key Challenge for TEM
Tempus faces headwinds primarily related to reimbursement challenges. The company’s certain product segments, such as its minimal residual disease (MRD) and TRM portfolios, were gated due to the lack of reimbursement in the second quarter. Without payer coverage, Tempus cannot scale volumes in these areas, which limits both revenue growth and margin expansion potential.
TEM Stock Expensive Valuation
With a forward five-year price-to-sales (P/S) of 9.41X, Tempus’ shares are trading at a premium compared with the industry average of 5.84X. It has a Value Score of F at present.
Image Source: Zacks Investment Research
Meanwhile, AZTA’s five-year P/S of 2.24X is also lower than the industry average. But, TXG’s shares are trading at a discount (five-year P/S of 2.84X) compared with the industry average.
How to Play TEM Stock?
Tempus delivered a strong second quarter with exceptional revenue and profit growth, driven by strategic acquisitions, innovative product launches, and segmental business growth. The company’s raised sales guidance and improving adjusted EBITDA outlook reflect its solid execution and growth potential.
While a strong balance sheet and expanding AI-driven healthcare solutions position Tempus for long-term success, reimbursement challenges in certain product segments remain a key hurdle to scaling revenues and margins. With shares already trading at elevated levels, we advise those who already have this Zacks Rank #3 (Hold) stock in their portfolios to maintain their position, while others may wait for a more favorable entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Key Takeaways
Tempus AI (TEM - Free Report) posted robust second-quarter results and raised the sales guidance for 2025 for the second time within six months. Full-year revenues are now expected to be approximately $1.26 billion (earlier $1.25 billion), indicating nearly 82% annual growth. The company recorded second-quarter revenue growth of 89.6%. The quarterly gross profit soared 158.3% from the year-ago quarter’s level.
Additionally, adjusted gross margin expanded 1649 bps, despite a 32.2% rise in the cost of revenues. Meanwhile, Tempus AI experienced another quarter of sequential improvement in adjusted EBITDA, which went from a negative $16 million in the previous quarter to a negative $5.6 million in the second quarter. This improvement made the company expect a positive adjusted EBITDA of $5 million in 2025.
On the innovation side, Tempus AI continued to push boundaries. Recently, the company expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer to address critical care gaps in breast cancer care. It also introduced xM, a liquid biopsy assay, for treatment response monitoring (TRM), to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors.
Year to date, TEM stock has skyrocketed 137.6%, outperforming the Medical Info Systems industry and the S&P 500 benchmark, which have improved about 24.7% and 10.8%, respectively. The company has also outperformed other players in the health infotech field, such as Azenta, Inc. (AZTA - Free Report) and 10x Genomics, Inc. (TXG - Free Report) , which have lost 41% and 2.9%, respectively, during the said period.
YTD TEM’s Price Performance
Image Source: Zacks Investment Research
With strong financial growth and groundbreaking innovations, Tempus AI is rapidly positioning itself as a leader in precision medicine and AI-driven healthcare. For investors, now is the time to gauge just how big this runway could get.
Developments Propelling TEM’s Growth
Key Acquisitions Strengthening Its Leadership Position: Tempus announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition, valued at $81.25 million, is expected to enable Tempus to expand its dataset and strengthen its experienced technical team.
Additionally, in March, Tempus acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. The Deep 6 AI deal expanded Tempus' reach to 30M patient records across 750 healthcare providers.
Furthermore, earlier this year, Tempus completed the acquisition of Ambry Genetics, a genetic testing company that specializes in hereditary cancer screening and other genetic diseases. By combining Ambry’s genetic testing strengths with Tempus’ AI and data tools, the latter broadened its healthcare offerings into new areas, like pediatrics, women's health, rare disease, immunology and cardiology.
Robust Segmental Performance: In the second quarter, Tempus reported robust growth in its Genomics business with sales surging 115% year over year, driven by accelerating oncology testing volumes, which rose 26%. The hereditary testing segment also contributed significantly, with volumes up 32%, benefiting from both market share gains and overall industry tailwinds.
Meanwhile, Data and Services revenues grew 35.7%, led by a 41% rise in Insights, the company’s data licensing business. This growth was fueled by strong demand from large pharma partnerships, including the recently signed AstraZeneca Pathos deal, which contributed around $16 million in revenues for the quarter.
Strong Balance Sheet: Tempus exited the second quarter of 2025 with $293.0 million in cash and marketable securities, reflecting an improvement of approximately $70 million over the previous quarter. The company reported no current debt during the quarter, indicating strong solvency. Just after quarter end, Tempus AI completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing its balance sheet and allowing it to replace a portion of the existing term loan with a significantly lower interest debt instrument.
Estimates for TEM Heading South
The Zacks Consensus Estimate for Tempus’ 2025 sales and EPS implies a year-over-year improvement of 81.2% and 56.3%, respectively. However, in the past 30 days, Tempus’ loss per share estimate for 2025 has moved south 3%.
Image Source: Zacks Investment Research
Key Challenge for TEM
Tempus faces headwinds primarily related to reimbursement challenges. The company’s certain product segments, such as its minimal residual disease (MRD) and TRM portfolios, were gated due to the lack of reimbursement in the second quarter. Without payer coverage, Tempus cannot scale volumes in these areas, which limits both revenue growth and margin expansion potential.
TEM Stock Expensive Valuation
With a forward five-year price-to-sales (P/S) of 9.41X, Tempus’ shares are trading at a premium compared with the industry average of 5.84X. It has a Value Score of F at present.
Image Source: Zacks Investment Research
Meanwhile, AZTA’s five-year P/S of 2.24X is also lower than the industry average. But, TXG’s shares are trading at a discount (five-year P/S of 2.84X) compared with the industry average.
How to Play TEM Stock?
Tempus delivered a strong second quarter with exceptional revenue and profit growth, driven by strategic acquisitions, innovative product launches, and segmental business growth. The company’s raised sales guidance and improving adjusted EBITDA outlook reflect its solid execution and growth potential.
While a strong balance sheet and expanding AI-driven healthcare solutions position Tempus for long-term success, reimbursement challenges in certain product segments remain a key hurdle to scaling revenues and margins. With shares already trading at elevated levels, we advise those who already have this Zacks Rank #3 (Hold) stock in their portfolios to maintain their position, while others may wait for a more favorable entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.